investments Tatva Chintan Pharma Chem is sustaining improving revenue and profitability trajectory. Buy for target price of ₹1955 (41% upside): ICICI Securities Arjun January 25, 2026 0 TATVA expects SDA revenue growth to sustain, with new customers’ offtake in CY26 and...Read More